Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-3.94 · Revenue $10.65M · 6 analysts
Est. EPS $-3.37 · Revenue $20.00M · 6 analysts
Est. EPS $-0.94 · Revenue $892200.00 · 4 analysts
Est. EPS $-0.97 · Revenue $696100.00 · 4 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $25.4M | -87.9% | +2.6% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-143.8M | -319.0% | -7.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +83.9% | -16.1% | +1150.0% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -613.7% | -2851.4% | -3.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -565.5% | -1916.2% | -4.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-129.6M | -189.7% | +22.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -509.6% | -2302.3% | +24.2% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 16.6% | +20.5% | +13.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 12.53x | +12.4% | -21.7% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $377.4M | -28.3% | -10.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -3.47 vs -3.61 | +3.8% | -1.01 vs -0.94 | -7.3% |
| Revenue Surprise | $25.4M vs $30.5M | -16.5% | $898000 vs $892200 | +0.7% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. | 10 percent owner | Common Stock | D | 32,263 | $7.17 |
| Sep 3, 2026 | MPM BioVentures 2014, L.P. | 10 percent owner | Common Stock | D | 32,263 | $7.17 |
| Sep 2, 2026 | MPM BIOVENTURES 2018, L.P. | 10 percent owner | Common Stock | D | 25,131 | $7.19 |
| Sep 2, 2026 | MPM BioVentures 2014, L.P. | 10 percent owner | Common Stock | D | 25,131 | $7.19 |
| Sep 2, 2026 | Doshi Dipal | director, officer: CEO | Common Stock | D | 8,724 | $7.14 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Dipal Doshi | Chief Executive Officer & Director | USD 998,250 | Male | 1976 | Active |
Natarajan Sethuraman | President of Research & Development | USD 768,000 | — | 1962 | Active |
Nathan J. Dowden | President & Chief Operating Officer | USD 737,182 | Male | 1971 | Active |
Karla MacDonald | Chief Corporate Affairs Officer | — | Female | — | Active |
Kerry Robert | Senior Vice President of People | — | Female | — | Active |
Sandeep Basnet | Head of Information Technology | — | — | — | Active |
Jared Cohen | General Counsel | — | — | — | Active |
Kory James Wentworth | Chief Financial Officer & Treasurer | — | Male | 1979 | Active |
Kevin Healy | Senior Vice President of Regulatory Affairs | — | Male | — | Active |
BlackRock Inc. purchased a new stake in Entrada Therapeutics, Inc. (NASDAQ: TRDA) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,583,333 shares of the company's stock, valued at approximately $19,013,000. BlackRock Inc. owned 6.65% of Entrada Therapeutics at
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company's common stock to eight newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026.
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to a loss of $1.04 per share a year ago.
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business updates. “With multiple data readouts ahead in 2026, we are well positioned to deliver on important clinical milestones and further demonstrate the potential of our DMD franchise,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
